Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates

Burns : Journal of the International Society for Burn Injuries
Abdulkader F TawfikMohamed H Al-Agamy

Abstract

We determined the prevalence rate of classes A, B and D β-lactamases among extended-spectrum cephalosporin (ESC)-non-susceptible Pseudomonas aeruginosa clinical isolates from burned patients. Disc susceptibility testing was performed on 156 P. aeruginosa isolates collected during 2010 at Prince Salman Hospital in Riyadh, Saudi Arabia. Phenotypic screening of ESBLs and MBLs in the isolates resistant to ceftazidime (MIC>8 mg/L) was carried out. Genes encoding ESBLs and MBL were sought by PCR in ESBL- and MBL-producing isolates. The resistance rate to ceftazidime was 22.43%. The resistance rates for ESC-non-susceptible P. aeruginosa isolates to piperacillin, piperacillin/tazobactam, cefepime, aztreonam, imipenem, amikacin, gentamicin and ciprofloxacin were 100%, 71.14%, 88.57%, 48.57%, 70.0%, 82.5%, 87.5%, and 90.0% respectively. No resistance was detected to polymyxine B. The prevalence of ESBL and MBL in ESC-non-susceptible P. aeruginosa was 69.44% and 42.85%, respectively. The prevalence of structural genes for VEB-1, OXA-10 and GES ESBLs in P. aeruginosa was 68%, 56% and 20%, respectively. VIM gene was detected in 15 (100%) of MBL-producing isolates. OXA-10 like gene was concomitant with VEB, GES and/or VIM. Eight isolates har...Continue Reading

References

Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Gerhard F WeldhagenPatrice Nordmann
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Pierre BogaertsYouri Glupczynski
Mar 7, 2009·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Freshteh ShahcheraghiMohammad Mehdi Feizabadi
Jun 16, 2009·Burns : Journal of the International Society for Burn Injuries·Akbar MirsalehianNarges Kalantari
Sep 2, 2009·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Dec 17, 2009·The Journal of Antimicrobial Chemotherapy·Damien FournierPatrick Plésiat
Feb 9, 2010·The Journal of Antimicrobial Chemotherapy·Renata C PicãoAna C Gales
Feb 27, 2010·International Journal of Antimicrobial Agents·Jie WangLan-juan Li
Jun 12, 2010·International Journal of Medical Microbiology : IJMM·Yvonne PfeiferWolfgang Witte
Mar 24, 2011·The Journal of Antimicrobial Chemotherapy·Martin KaaseLaurent Poirel
Jul 13, 2011·Frontiers in Microbiology·Keith Poole

❮ Previous
Next ❯

Citations

Jul 5, 2013·Clinical Microbiology Reviews·Hosam M ZowawiDavid L Paterson
Nov 25, 2014·Journal of Medical Microbiology·Saber YezliZiad A Memish
Apr 29, 2014·Burns : Journal of the International Society for Burn Injuries·Davood Kalantar NeyestanakiMohammad Emaneini
Oct 16, 2015·Jundishapur Journal of Microbiology·Sanaz Pakbaten ToupkanlouRahim Pirhajati Mahabadi
Jan 9, 2015·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ziad A MemishSaber Yezli
Sep 7, 2016·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Mohamed H Al-AgamyPatrice Courvalin
Dec 2, 2015·Antimicrobial Agents and Chemotherapy·Diansy ZinckeKalai Mathee
Feb 28, 2020·Clinical Microbiology Reviews·Karen Bush, Patricia A Bradford
Nov 6, 2020·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.